Advertisement

Drugs

, Volume 70, Issue 11, pp 1445–1476 | Cite as

Rituximab

A Review of its Use in Chronic Lymphocytic Leukaemia, Low-Grade or Follicular Lymphoma and Diffuse Large B-Cell Lymphoma
  • Gillian M. KeatingEmail author
Adis Drug Evaluation

Abstract

Rituximab (MabThera®, Rituxan®) is a chimeric mouse anti-human CD20 monoclonal antibody. This article reviews the use of intravenous rituximab in the treatment of chronic lymphocytic leukaemia (CLL), low-grade or follicular lymphoma, and diffuse large B-cell lymphoma.

The addition of rituximab to fludarabine plus cyclophosphamide significantly prolonged progression-free survival both in previously untreated patients with CLL and in those with relapsed or refractory CLL, according to the results of two randomized, open-label, multicentre trials.

In patients with previously untreated advanced follicular lymphoma, the addition of rituximab to chemotherapy (cyclophosphamide, doxorubicin, vincristine and prednisone [CHOP], cyclophosphamide, vincristine and prednisone [CVP], mitoxantrone, chlorambucil and prednisolone, or cyclophosphamide, doxorubicin, etoposide and prednisolone) was generally associated with better outcomes than chemotherapy alone in randomized, multicentre trials. In a similarly designed trial, progression-free survival was significantly longer in previously untreated patients with follicular lymphoma, other indolent lymphomas or mantle-cell lymphoma who received rituximab plus bendamustine than in those receiving rituximab plus CHOP. Monotherapy with rituximab also demonstrated efficacy in patients with relapsed or refractory low-grade or follicular lymphoma, according to the results of noncomparative trials. In terms of maintenance therapy, progression-free survival was significantly prolonged with rituximab maintenance therapy versus observation alone in patients with advanced indolent lymphoma who had not progressed following first-line therapy with CVP and in patients with relapsed or refractory follicular lymphoma who had responded to CHOP (with or without rituximab), according to the results of randomized, open-label, multicentre trials.

In four randomized, open-label, multicentre trials in younger or elderly patients with previously untreated diffuse large B-cell lymphoma, event-free survival, failure-free survival, progression-free survival and overall survival were generally improved to a significant extent by the addition of rituximab to CHOP or CHOP-like chemotherapy.

Intravenous rituximab was generally well tolerated in patients with CLL, low-grade or follicular lymphoma, or diffuse large B-cell lymphoma, both as monotherapy and when administered in combination with chemotherapy. Infusion reactions were one of the most commonly occurring adverse events in patients receiving intravenous rituximab.

The results of pharmacoeconomic modelling analyses demonstrated that rituximab appears to be cost effective in patients with previously untreated follicular lymphoma, in patients with follicular lymphoma receiving rituximab maintenance therapy following treatment for relapsed or refractory disease and in patients with previously untreated diffuse large B-cell lymphoma.

In conclusion, rituximab remains a valuable therapy in patients with CLL, low-grade or follicular lymphoma and diffuse large B-cell lymphoma and, in a variety of treatment settings, represents the standard of care.

Keywords

Chronic Lymphocytic Leukaemia Follicular Lymphoma Progressive Multifocal Leukoencephalopathy Fludarabine Alemtuzumab 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Winter MC, Hancock BW. Ten years of rituximab in NHL. Expert Opin Drug Saf 2009 Mar; 8(2): 223–35PubMedCrossRefGoogle Scholar
  2. 2.
    Foster T, Miller JD, Boye ME, et al. Economic burden of follicular non-Hodgkin’s lymphoma. Pharmacoeconomics 2009; 27(8): 657–79PubMedCrossRefGoogle Scholar
  3. 3.
    National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology™: non-Hodgkin’s lymphoma (v.1.2010) [online]. Available from URL: http://www.nccn.org/professionals/physician_gls/PDF/nhl.pdf [Accessed 2010 Mar 22]
  4. 4.
    Robak T, Dmoszynska A, Solal-Céligny P. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 2010 Apr 1; 28(10): 1756–65PubMedCrossRefGoogle Scholar
  5. 5.
    Hagemeister F. Rituximab for the treatment of non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia. Drugs 2010; 70(3): 261–72PubMedCrossRefGoogle Scholar
  6. 6.
    Bello C, Sotomayor EM. Monoclonal antibodies for B-cell lymphomas: rituximab and beyond. Hematology Am Soc Hematol Educ Program 2007: 233–42Google Scholar
  7. 7.
    Sonet A, Bosly A. Rituximab and chemotherapy in diffuse large B-cell lymphoma. Expert Rev Anticancer Ther 2009 Jun; 9(6): 719–26PubMedCrossRefGoogle Scholar
  8. 8.
    Jazirehi AR, Bonavida B. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin’s lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene 2005 Mar 24; 24(13): 2121–43PubMedCrossRefGoogle Scholar
  9. 9.
    Genentech, Inc. Rituxan (rituximab) injection for intravenous use: US prescribing information [online]. Available from URL: http://www.gene.com/gene/products/information/pdf/rituxan-prescribing.pdf [Accessed 2010 Mar 22]
  10. 10.
    European Medicines Agency. MabThera (rituximab) 100 mg (10 mg/mL) concentrate for solution for infusion: summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu/humandocs/PDFs/EPAR/Mabthera/emea-combined-h165en.pdf [Accessed 2010 Mar 22]
  11. 11.
    Vega MI, Huerta-Yepez S, Martinez-Paniagua M, et al. Rituximab-mediated cell signaling and chemo/immuno-sensitization of drug-resistant B-NHL is independent of its Fc functions. Clin Cancer Res 2009 Nov 1; 15(21): 6582–94PubMedCrossRefGoogle Scholar
  12. 12.
    Vega MI, Huerta-Yepez S, Jazirehi AR, et al. Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fasinduced apoptosis. Oncogene 2005 Dec 8; 24(55): 8114–27PubMedGoogle Scholar
  13. 13.
    Foon KA, Hallek MJ. Changing paradigms in the treatment of chronic lymphocytic leukemia. Leukemia 2010 Mar; 24(3): 500–11PubMedCrossRefGoogle Scholar
  14. 14.
    Selenko N, Majdic O, Draxler S, et al. CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells. Leukemia 2001 Oct; 15(10): 1619–26PubMedCrossRefGoogle Scholar
  15. 15.
    Cartron G, Blasco H, Paintaud G, et al. Pharmacokinetics of rituximab and its clinical use: thought for the best use? Crit Rev Oncol Hematol 2007 Apr; 62(1): 43–52PubMedCrossRefGoogle Scholar
  16. 16.
    Tran L, Huitema ADR, Aarden L, et al. Phamacokinetics of rituximab and the development of antibodies against rituximab in patients with a B-cell CD20+ malignancy [abstract no. 0975]. 14th Congress of the European Hematology Association; 2009 Jun 4–7; BerlinGoogle Scholar
  17. 17.
    Berinstein NL, Grillo-López AJ, White CA, et al. Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin’s lymphoma. Ann Oncol 1998 Sep; 9(9): 995–1001PubMedCrossRefGoogle Scholar
  18. 18.
    Blasco H, Chatelut E, Benz de Bretagne I, et al. Pharmacokinetics of rituximab associated with CHOP chemotherapy in B-cell non-Hodgkin lymphoma. Fundam Clin Pharmacol 2009 Oct; 23(5): 601–8PubMedCrossRefGoogle Scholar
  19. 19.
    Rodriguez J, Gutierrez A. Pharmacokinetic properties of rituximab. Rev Recent Clin Trials 2008 Jan; 3(1): 22–30PubMedCrossRefGoogle Scholar
  20. 20.
    Li J, Levi M, Charoin J-E, et al. Rituximab exhibits a long half-life based on a population pharmacokinetic analysis in non-Hodgkin’s lymphoma (NHL) patients [abstract no. 2371]. Blood 2007 Nov 16; 110 (11 Pt 1): 700Google Scholar
  21. 21.
    Scheidhauer K, Wolf I, Baumgartl H-J, et al. Biodistribution and kinetics of 131I-labelled anti-CD20 MAB IDEC-C2B8 (rituximab) in relapsed non-Hodgkin’s lymphoma. Eur J Nucl Med Mol Imaging 2002 Oct; 29(10): 1276–82PubMedCrossRefGoogle Scholar
  22. 22.
    Li J, Zhi J, Wenger MK, et al. Higher doses of rituximab may be required for patients with CLL as compared to NHL based on population pharmacokinetic (PK) modelling [abstract no. 1742]. 51st Annual Meeting and Exposition of the American Society of Hematology; 2009 Dec 5–8; New Orleans (LA)Google Scholar
  23. 23.
    Yin A, Li J, Hurst D, et al. Population pharmacokinetics (PK) and association of PK and clinical outcomes of rituximab in patients with non-Hodgkin’s lymphoma [abstract no. 13108]. 46th Annual Meeting of the American Society of Clinical Oncology; 2010 Jun 4–8; Chicago (IL)Google Scholar
  24. 24.
    Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994 Sep 1; 84(5): 1361–92PubMedGoogle Scholar
  25. 25.
    Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting: Airlie House, Virginia, November 1997. J Clin Oncol 1999 Dec; 17(12): 3835–49PubMedGoogle Scholar
  26. 26.
    Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981 Jul 1; 48(1): 198–206PubMedCrossRefGoogle Scholar
  27. 27.
    Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocytic leukemia. Blood 1975 Aug; 46(2): 219–34PubMedGoogle Scholar
  28. 28.
    Zinzani PL. Lymphoma: diagnosis, staging, natural history, and treatment strategies. Semin Oncol 2005 Feb; 32 (1 Pt 2): 4–10CrossRefGoogle Scholar
  29. 29.
    Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996 Jun 15; 87(12): 4990–7PubMedGoogle Scholar
  30. 30.
    Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the international workshop on chronic lymphocytic leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008 Jun 15; 111(12): 5446–56PubMedCrossRefGoogle Scholar
  31. 31.
    Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. J Clin Oncol 1999 Apr; 17(4): 1244–53PubMedGoogle Scholar
  32. 32.
    Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007 Feb 10; 25(5): 579–86PubMedCrossRefGoogle Scholar
  33. 33.
    Hallek M, Fingerle-Rowson G, Fink A-M, et al. First-line treatment with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) improves overall survival (OS) in previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL): results of a randomized phase III trial on behalf of an international group of investigators and the German CLL Study Group [abstract no. 535]. 51st Annual Meeting and Exposition of the American Society of Hematology; 2009 Dec 5–8; New Orleans (LA)Google Scholar
  34. 34.
    Keating MJ, O’Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005 Jun 20; 23(18): 4079–88PubMedCrossRefGoogle Scholar
  35. 35.
    Tam CS, O’Brien S, Wierda W, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008 Aug 15; 112(4): 975–80PubMedCrossRefGoogle Scholar
  36. 36.
    Wierda W, O’Brien S, Wen S, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005 Jun 20; 23(18): 4070–8PubMedCrossRefGoogle Scholar
  37. 37.
    Lepretre S, Aurran T, Mahe B, et al. Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine (F), cyclophosphamide (C) and MabCampath (Cam) (FCCam) in previously untreated patients (pts) with advanced B-chronic lymphocytic leukemia (B-CLL): experience on safety and efficacy within a randomised multicenter phase III trial of the French Cooperative Group on CLL and WM (FCGCLL/MW) and the ‘Groupe Ouest-Est d’Etudes Des Leucémies Aigües et Autres Maladies du Sang’ (GOELAMS): CLL2007FMP (for fit medically patients) [abstract no. 538]. 51st Annual Meeting and Exposition of the American Society of Hematology; 2009 Dec 5–8; New Orleans (LA)Google Scholar
  38. 38.
    Groupe Ouest Est d’Etude des Leucémies et Autres Maladies du Sang GOELAMS. Fludarabine, cyclophosphamide, and rituximab or alemtuzumab in treating patients with B-cell chronic lymphocytic leukemia [ClinicalTrials.gov identifier NCT00564512]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from: http://www.clinicaltrials.gov [Accessed 2010 Mar 25]
  39. 39.
    Del Poeta G, Del Principe MI, Maurillo L, et al. Oral fludarabine plus rituximab result in high complete remission rate in B-cell chronic lymphocytic leukemia [abstract no. 0094]. Haematologica 2008 Jun 1; 93 Suppl. 1: 37Google Scholar
  40. 40.
    Fischer K, Cramer P, Stilgenbauer S, et al. Bendamustine combined with rituximab (BR) in first-line therapy of advanced CLL: a multicenter phase II trial of the German CLL Study Group (GCLLSG) [abstract no. 205]. 51st Annual Meeting and Exposition of the American Society of Hematology; 2009 Dec 5–8; New Orleans (LA)Google Scholar
  41. 41.
    Hillmen P, Gribben JG, Follows GA, et al. An open-label phase II study to investigate the safety and efficacy of rituximab plus chlorambucil in previously untreated patients with CD20-positive B-cell chronic lymphocytic leukaemia (CLL) [abstract no. 3428]. 51st Annual Meeting and Exposition of the American Society of Hematology; 2009 Dec 5–8; New Orleans (LA)Google Scholar
  42. 42.
    Kay NE, Geyer SM, Call TG, et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 2007 Jan 15; 109(2): 405–11PubMedCrossRefGoogle Scholar
  43. 43.
    Bosch F, Abrisqueta P, Villamor N, et al. Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia. J Clin Oncol 2009 Sep 20; 27(27): 4578–84PubMedCrossRefGoogle Scholar
  44. 44.
    Faderl S, Wierda W, O’Brien S, et al. Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 years. Leuk Res 2010 Mar; 34(3): 284–8PubMedCrossRefGoogle Scholar
  45. 45.
    Frankfurt O, Hamilton E, Duffey S, et al. Alemtuzumab and rituximab combination therapy for patients with untreated CLL: a phase II trial [abstract no. 2098]. 50th Annual Meeting and Exposition of the American Society of Hematology; 2008 Dec 6–9; San Francisco (CA)Google Scholar
  46. 46.
    Zent CS, Call TG, Shanafelt TD, et al. Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab. Cancer 2008 Oct 15; 113(8): 2110–8PubMedCrossRefGoogle Scholar
  47. 47.
    Parikh SA, Keating M, O’Brien S, et al. Frontline combined chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab and rituximab (CFAR) in high-risk chronic lymphocytic leukemia [abstract no. 208]. 51st Annual Meeting and Exposition of the American Society of Hematology; 2009 Dec 5–8; New Orleans (LA)Google Scholar
  48. 48.
    Wierda WG, O’Brien S, Ferrajoli A, et al. Combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR), an active frontline regimen for high-risk patients with CLL [abstract no. 628]. Blood 2007 Nov 16; 110 (11 Pt 1): 194aGoogle Scholar
  49. 49.
    Castro JE, James DF, Sandoval-Sus JD, et al. Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia. Leukemia 2009 Oct; 23(10): 1779–89PubMedCrossRefGoogle Scholar
  50. 50.
    Eichhorst BF, Fischer K, Fink A-M, et al. Health related quality of life (HRQOL) in patients receiving chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) or fludarabine and cyclophosphamide (FC) for first line therapy with advanced chronic lymphocytic leukemia (CLL) [abstract no. 3438]. 51st Annual Meeting and Exposition of the American Society of Hematology; 2009 Dec 5–8; New Orleans (LA)Google Scholar
  51. 51.
    Fischer K, Stilgenbauer S, Schweighofer CD, et al. Bendamustine in combination with rituximab (BR) for patients with relapsed chronic lymphocytic leukemia (CLL): a multicentre phase II trial of the German CLL study group (GCLLSG) [abstract no. 330]. 50th Annual Meeting and Exposition of the American Society of Hematology; 2008 Dec 6–9; San Francisco (CA)Google Scholar
  52. 52.
    Tsimberidou AM, Wierda WG, Plunkett W, et al. Phase I–II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter’s syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2008 Jan 10; 26(2): 196–203PubMedCrossRefGoogle Scholar
  53. 53.
    Tsimberidou A-M, Wierda W, Plunkett W, et al. Oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy induces high response rates in agressive chronic lymphocytic leukemia (CLL) and Richter’s syndrome (RS) [abstract no. 3443]. 51st Annual Meeting and Exposition of the American Society of Hematology; 2009 Dec 5–8; New Orleans (LA)Google Scholar
  54. 54.
    Lamanna N, Kalaycio M, Maslak P, et al. Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J Clin Oncol 2006 Apr 1; 24(10): 1575–81PubMedCrossRefGoogle Scholar
  55. 55.
    Lamanna N, Heaney ML, Brentjens RJ, et al. Pentostatin, cyclophosphamide, rituximab, and mitoxantrone: a new highly active regimen for patients with chronic lymphocytic leukemia (CLL) previously treated with PCR or FCR [abstract no. 3115]. Blood 2007 Nov 16; 110 (11 Pt 1): 916Google Scholar
  56. 56.
    Faderl S, Ferrajoli A, Wierda W, et al. Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukaemia recurrence. Cancer 2010 Mar 15; 116(10): 2360–5PubMedGoogle Scholar
  57. 57.
    Badoux XC, Keating M, O’Brien S, et al. Chemoimmunotherapy with cyclophosphamide, fludarabine, alemtuzumab and rituximab (CFAR) is effective in relapsed patients with chronic lymphocytic leukemia (CLL) [abstract no. 3431]. 51st Annual Meeting and Exposition of the American Society of Hematology; 2009 Dec 5–8; New Orleans (LA)Google Scholar
  58. 58.
    Bowen DA, Call TG, Jenkins GD, et al. Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features. Leuk Lymphoma 2007 Dec; 48(12): 2412–7PubMedCrossRefGoogle Scholar
  59. 59.
    Castro JE, Sandoval-Sus JD, Bole J, et al. Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia. Leukemia 2008 Nov 1; 22(11): 2048–53PubMedCrossRefGoogle Scholar
  60. 60.
    Dungarwalla M, Evans SO, Riley U, et al. High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy [letter]. Haematologica 2008 Mar; 93(3): 475–6PubMedCrossRefGoogle Scholar
  61. 61.
    Robak T, Aultman R, Oertel SHK, et al. Quality-adjusted survival (Q-TWiST) analysis of patients with relapsed or refractory chronic lymphocytic leukaemia treated with rituximab plus fludarabine and cyclophosphamide (R-FC) versus FC alone [abstract no. 1368]. 51st Annual Meeting and Exposition of the American Society of Hematology; 2009 Dec 5–8; New Orleans (LA)Google Scholar
  62. 62.
    Feuring-Buske M, Kneba M, Unterhalt M, et al. IDEC-C2B8 (rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group. Ann Hematol 2000 Sep; 79(9): 493–500PubMedCrossRefGoogle Scholar
  63. 63.
    Maloney DG, Grillo-López AJ, White CA, et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood 1997 Sep 15; 90(6): 2188–95PubMedGoogle Scholar
  64. 64.
    Davis TA, Grillo-López AJ, White CA, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin’s lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000 Sep; 18(17): 3135–43PubMedGoogle Scholar
  65. 65.
    Davis TA, White CA, Grillo-López AJ, et al. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin’s lymphoma: results of a phase II trial of rituximab. J Clin Oncol 1999 Jun; 17(6): 1851–7PubMedGoogle Scholar
  66. 66.
    Piro LD, White CA, Grillo-López AJ, et al. Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin’s lymphoma. Ann Oncol 1999; 10(6): 655–61PubMedCrossRefGoogle Scholar
  67. 67.
    McLaughlin P, Grillo-López AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998 Aug; 16(8): 2825–33PubMedGoogle Scholar
  68. 68.
    Herold M, Haas A, Srock S, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German study group hematology and oncology study. J Clin Oncol 2007 May 20; 25(15): 1986–92PubMedCrossRefGoogle Scholar
  69. 69.
    Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005 Dec 1; 106(12): 3725–32PubMedCrossRefGoogle Scholar
  70. 70.
    Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008 Oct 1; 26(28): 4579–86PubMedCrossRefGoogle Scholar
  71. 71.
    Salles G, Mounier N, de Guibert S, et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood 2008 Dec 15; 112(13): 4824–31PubMedCrossRefGoogle Scholar
  72. 72.
    Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany) [abstract no. 405]. 51st Annual Meeting and Exposition of the American Society of Hematology; 2009 Dec 5–8; New Orleans (LA)Google Scholar
  73. 73.
    Hochster H, Weller E, Gascoyne RD, et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 study. J Clin Oncol 2009 Apr 1; 27(10): 1607–14PubMedCrossRefGoogle Scholar
  74. 74.
    Marcus R, Aultman R, Jost F. A quality-adjusted survival analysis (Q-TWiST) of rituximab plus CVP vs CVP alone in first-line treatment of advanced follicular non-Hodgkin’s lymphoma. Br J Cancer 2010 Jan 5; 102(1): 19–22PubMedCrossRefGoogle Scholar
  75. 75.
    van Oers MHJ, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006 Nov 15; 108(10): 3295–301PubMedCrossRefGoogle Scholar
  76. 76.
    van Oers MH, Van Glabbeke M, Giurgea L, et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin’s lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol. Epub 2010 May 3Google Scholar
  77. 77.
    Foran JM, Gupta RK, Cunningham D, et al. A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response. Br J Haematol 2000 Apr; 109(1): 81–8PubMedCrossRefGoogle Scholar
  78. 78.
    Coiffier B, Lepage E, Brière J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002 Jan 24; 346(4): 235–42PubMedCrossRefGoogle Scholar
  79. 79.
    Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006 Jul 1; 24(19): 3121–7PubMedCrossRefGoogle Scholar
  80. 80.
    Pfreundschuh M, Trumper L, Osterborg A. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006 May; 7(5): 379–91PubMedCrossRefGoogle Scholar
  81. 81.
    Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008 Feb; 9(2): 105–16PubMedCrossRefGoogle Scholar
  82. 82.
    Delarue R, Tilly H, Salles G, et al. R-CHOP14 compared to R-CHOP21 in elderly patients with diffuse large B-cell lymphoma: results of the interim analysis of the LNH03-6B GELA study [abstract no. 406]. 51st Annual Meeting and Exposition of the American Society of Hematology; 2009 Dec 5–8; New Orleans (LA)Google Scholar
  83. 83.
    Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 2005 Jun 20; 23(18): 4117–26PubMedCrossRefGoogle Scholar
  84. 84.
    Coiffier B, Gisselbrecht C, Bosly A, et al. 10 years follow-up of the GELA LNH98.5 study, first randomized study comparing R-CHOP to CHOP chemotherapy in patients with diffuse large B-cell lymphoma [abstract no. 3741]. 51st Annual Meeting and Exposition of the American Society of Hematology; 2009 Dec 5–8; New Orleans (LA)Google Scholar
  85. 85.
    Boehme V, Schmitz N, Zeynalova S, et al. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood 2009 Apr 23; 113(17): 3896–902PubMedCrossRefGoogle Scholar
  86. 86.
    Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009 May 14; 113(20): 4834–40PubMedCrossRefGoogle Scholar
  87. 87.
    Hornberger J, Reyes C, Lubeck D, et al. Economic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma. Leuk Lymphoma 2008 Feb; 49(2): 227–36PubMedCrossRefGoogle Scholar
  88. 88.
    Ray JA, Carr E, Lewis G, et al. An evaluation of the cost-effectiveness of rituximab in combination with chemotherapy for the first-line treatment of follicular non-Hodgkin’s lymphoma in the UK. Value Health. Epub 2010 Jan 8Google Scholar
  89. 89.
    Deconinck E, Miadi-Fargier H, Le Pen C, et al. Cost effectiveness of rituximab maintenance therapy in follicular maintenance therapy in follicular lymphoma: long-term economic evaluation. Pharmacoeconomics 2010; 28(1): 35–46PubMedCrossRefGoogle Scholar
  90. 90.
    Hayslip JW, Simpson KN. Cost-effectiveness of extended adjuvant rituximab for US patients aged 65–70 years with follicular lymphoma in second remission. Clin Lymphoma Myeloma 2008 Jun; 8(3): 166–70PubMedCrossRefGoogle Scholar
  91. 91.
    Kasteng F, Erlanson M, Hagberg H, et al. Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden. Acta Oncol 2008; 47(6): 1029–36PubMedCrossRefGoogle Scholar
  92. 92.
    Hornberger JC, Best JH. Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma. Cancer 2005 Apr 15; 103(8): 1644–51PubMedCrossRefGoogle Scholar
  93. 93.
    Foon KA, Boyiadzis M, Land SR, et al. Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009 Feb 1; 27(4): 498–503PubMedCrossRefGoogle Scholar
  94. 94.
    Lamanna N, Jurcic JG, Noy A, et al. Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses. J Clin Oncol 2009 Feb 1; 27(4): 491–7PubMedCrossRefGoogle Scholar
  95. 95.
    Ahmadi T, Schuster SJ. Variations on the fludarabine, cyclophosphamide, and rituximab combination in chronic lymphocytic leukemia therapy: what have we learned? J Clin Oncol 2009 Feb 1; 27(4): 479–80PubMedCrossRefGoogle Scholar
  96. 96.
    National Cancer Institute. Adult non-Hodgkin’s lymphoma treatment (PDQ®) health professional version [online]. Available from URL: http://www.cancer.gov/cancerinfo/pdq/treatment/adult-non-hodgkins/healthprofessional [Accessed 2010 Mar 22]
  97. 97.
    Horning SJ. Follicular lymphoma, survival, and rituximab: is it time to declare victory? J Clin Oncol 2008 Oct 1; 26(28): 4537–8PubMedCrossRefGoogle Scholar
  98. 98.
    van Oers MHJ. Rituximab maintenance therapy: a step forward in follicular lymphoma. Haematologica 2007 Jun; 92(6): 826–33PubMedCrossRefGoogle Scholar
  99. 99.
    Vidal L, Gafter-Gvili A, Leibovici L, et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials. J Natl Cancer Inst 2009 Feb 18; 101(4): 248–55PubMedCrossRefGoogle Scholar
  100. 100.
    Salles GA, Seymour JF, Feugier P, et al. Rituximab maintenance for 2 years in patients with untreated high tumor burden follicular lymphoma after response to chemotherapy [abstract no. 8004]. 46th Annual Meeting of the American Society of Clinical Oncology; 2010 Jun 4–8; Chicago (IL)Google Scholar
  101. 101.
    Eastern Cooperative Oncology Group. Rituximab in treating patients with low tumor burden indolent non-Hodgkin’s lymphoma [ClinicalTrials.gov identifier NCT00075946]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2010 Apr 19]
  102. 102.
    Ternant D, Hénin E, Cartron G, et al. Development of a drug-disease simulation model for rituximab in follicular non-Hodgkin’s lymphoma. Br J Clin Pharmacol 2009 Oct; 68(4): 561–73PubMedCrossRefGoogle Scholar
  103. 103.
    Sehn LH, Donaldson J, Filewich A, et al. Rapid infusion rituximab in combination with corticosteroid-containing chemotherapy or as maintenance therapy is well tolerated and can safely be delivered in the community setting. Blood 2007 May 15; 109(10): 4171–3PubMedCrossRefGoogle Scholar
  104. 104.
    National Cancer Institute. Chronic lymphocytic leukemia treatment (PDQ®) health professional version [online]. Available from URL: http://www.cancer.gov/cancertopics/pdq/treatment/CLL/healthprofessional/allpages [Accessed 2010 Mar 22]
  105. 105.
    Solal-Céligny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004 Sep 1; 104(5): 1258–65PubMedCrossRefGoogle Scholar
  106. 106.
    A predictive model for aggressive non-Hodgkin’s lymphoma: the International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med 1993 Sep 30; 329 (14): 987–94Google Scholar
  107. 107.
    Ziepert M, Hasenclever D, Kuhnt E, et al. Standard International Prognostic Index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol 2010 May 10; 28(14): 2373–80PubMedCrossRefGoogle Scholar
  108. 108.
    Czuczman MS, Grillo-López AJ, Alkuzweny B, et al. Prognostic factors for non-Hodgkin’s lymphoma patients treated with chemotherapy may not predict outcome in patients treated with rituximab. Leuk Lymphoma 2006 Sep; 47(9): 1830–40PubMedCrossRefGoogle Scholar
  109. 109.
    Maeshima AM, Taniguchi H, Nomoto J, et al. Histological and immunophenotypic changes in 59 cases of B-cell non-Hodgkin’s lymphoma after rituximab therapy. Cancer Sci 2009 Jan; 100(1): 54–61PubMedCrossRefGoogle Scholar
  110. 110.
    Winter JN, Li S, Aurora V, et al. Expression of p21 protein predicts clinical outcome in DLBCL patients older than 60 years treated with R-CHOP but not CHOP: a prospective ECOG and Southwest Oncology Group correlative study on E 4494. Clin Cancer Res 2010 Apr 15; 16(8): 2435–42PubMedCrossRefGoogle Scholar
  111. 111.
    Weng W-K, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003 Nov 1; 21(21): 3940–7PubMedCrossRefGoogle Scholar
  112. 112.
    Friedberg JW, Younes A, Fisher DC, et al. Durable responses in patients treated with galiximab (anti-CD80) in combination with rituximab for relapsed or refractory follicular lymphoma: long-term follow-up of a phase II clinical trial [abstract no. 1004]. 50th Annual Meeting and Exposition of the American Society of Hematology; 2008 Dec 6–9; San Francisco (CA)Google Scholar
  113. 113.
    Blum KA, Baiocchi RA, Alinari L, et al. A phase II trial of induction plus maintenance rituximab and bortezomib in patients with relapsed/refractory mantle cell (MCL) and follicular (FL) non-Hodgkin’s lymphoma [abstract no. 3053]. 50th Annual Meeting and Exposition of the American Society of Hematology; 2008 Dec 6–9; San Francisco (CA)Google Scholar
  114. 114.
    David KA, Smith MR, Lossos IS, et al. A phase II trial of combination bortezomib (Velcade®) and rituximab for untreated ‘high tumor burden’ indolent non-Hodgkin lymphoma [abstract no. 2004]. 50th Annual Meeting and Exposition of the American Society of Hematology; 2008 Dec 6–9; San Francisco (CA)Google Scholar
  115. 115.
    Pregno P, Chiappella A, Zinzani PL, et al. Activity and safety of bortezomib and rituximab in relapsed/refractory indolent non follicular and mantle-cell non Hodgkin lymphoma: a phase II multicenter study by Intergruppo Italiano Linfomi [abstract no. 0411]. 14th Congress of the European Hematology Association; 2009 Jun 4–7; BerlinGoogle Scholar
  116. 116.
    Fowler N, McLaughlin P, Hagemeister FB, et al. A biologic combination of lenalidomide and rituximab for frontline therapy of indolent B-cell non-Hodgkin’s lymphoma [abstract no. 1714]. 51st Annual Meeting and Exposition of the American Society of Hematology; 2009 Dec 5–8; New Orleans (LA)Google Scholar
  117. 117.
    Dutia M, DeRoock I, Chee K, et al. R2: preliminary results of a phase II study of lenalidomide and rituximab in relapsed/refractory indolent non-Hodgkin’s lymphoma (NHL) [abstract no. 1679]. 51st Annual Meeting and Exposition of the American Society of Hematology; 2009 Dec 5–8; New Orleans (LA)Google Scholar
  118. 118.
    Byrd JC, Kipps TJ, Flinn IW, et al. Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. Blood 2010 Jan 21; 115(3): 489–95PubMedCrossRefGoogle Scholar
  119. 119.
    Ferrajoli A, Badoux XC, O’Brien S, et al. Combination therapy with lenalidomide and rituximab in patients with relapsed chronic lymphocytic leukemia (CLL) [abstract no. 206]. 51st Annual Meeting and Exposition of the American Society of Hematology; 2009 Dec 5–8; New Orleans (LA)Google Scholar

Copyright information

© Adis Data Information BV 2010

Authors and Affiliations

  1. 1.Adis, a Wolters Kluwer BusinessMairangi Bay, North Shore, AucklandNew Zealand

Personalised recommendations